Lipum's rights issue was subscribed to 42.6 per cent, of which approximately 35.7 percent was secured through subscription commitments. This means that the company will receive approximately SEK 79.7 million, which will be used to complete the phase I study with SOL-116, manufacturing and other preparations for phase II.
- I would like to extend a big thank you to everyone who participated in the rights issue. Our successful development can continue according to plan, says CEO Ola Sandborgh.

Read the full article at biostock.se:

https://www.biostock.se/en/2024/04/lipums-ceo-looks-ahead-after-the-rights-issue/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

https://news.cision.com/lipum-ab/r/biostock-lipum-s-ceo-looks-ahead-after-the-rights-issue,c3969240

(c) 2024 Cision. All rights reserved., source Press Releases - English